Literature DB >> 15711342

Urologic diseases in America Project: analytical methods and principal findings.

Mark S Litwin1, Christopher S Saigal, Elizabeth M Yano, Chantal Avila, Sandy A Geschwind, Jan M Hanley, Geoffrey F Joyce, Rodger Madison, Jennifer Pace, Suzanne M Polich, Mingming Wang.   

Abstract

PURPOSE: The burden of urological diseases on the American public is immense in human and financial terms but it has been under studied. We undertook a project, Urologic Diseases in America, to quantify the burden of urological diseases on the American public.
MATERIALS AND METHODS: We identified public and private data sources that contain population based data on resource utilization by patients with benign and malignant urological conditions. Sources included the Centers for Medicare and Medicaid Services, National Center for Health Statistics, Medical Expenditure Panel Survey, National Health and Nutrition Examination Survey, Department of Veterans Affairs, National Association of Children's Hospitals and Related Institutions, and private data sets maintained by MarketScan Health and Productivity Management (MarketScan, Chichester, United Kingdom), Ingenix (Ingenix, Salt Lake City, Utah) and Center for Health Care Policy and Evaluation. Using diagnosis and procedure codes we described trends in the utilization of urological services.
RESULTS: In 2000 urinary tract infections accounted for more than 6.8 million office visits and 1.3 million emergency room visits, and 245,000 hospitalizations in women with an annual cost of more than 2.4 billion dollars. Urinary tract infections accounted for more than 1.4 million office visits, 424,000 emergency room visits and 121,000 hospitalizations in men with an annual cost of more than 1 billion dollars. Benign prostatic hyperplasia was the primary diagnosis in more than 4.4 million office visits, 117,000 emergency room visits and 105,000 hospitalizations, accounting for 1.1 billion dollars in expenditures that year. Urolithiasis was the primary diagnosis for almost 2 million office visits, more than 600,000 emergency room visits, and more than 177,000 hospitalizations, totaling more than 2 billion dollars in annual expenditures. Urinary incontinence in women was the primary cause for more than 1.1 million office visits in 2000 and 452 million dollars in aggregate primary cause for more than 1.1 million office visits in 2000 and 452 million dollars in aggregate annual expenditures. Other manuscripts in this series present further detail for specific urologic conditions.
CONCLUSIONS: Recent trends in epidemiology, practice patterns, resource utilization and costs for urological diseases have broad implications for quality of health care, access to care and the equitable allocation of scarce resources for clinical care and research.

Entities:  

Mesh:

Year:  2005        PMID: 15711342     DOI: 10.1097/01.ju.0000152365.43125.3b

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  86 in total

1.  Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract.

Authors:  M Chelsea Lane; Virginia Lockatell; Greta Monterosso; Daniel Lamphier; Julia Weinert; J Richard Hebel; David E Johnson; Harry L T Mobley
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

2.  Characteristics of the phagocytic cup induced by uropathogenic Escherichia coli.

Authors:  Huaibin Wang; Feng-Xia Liang; Xiang-Peng Kong
Journal:  J Histochem Cytochem       Date:  2008-03-17       Impact factor: 2.479

3.  Survival of uropathogenic Escherichia coli in the murine urinary tract is dependent on OmpR.

Authors:  William R Schwan
Journal:  Microbiology (Reading)       Date:  2009-04-21       Impact factor: 2.777

4.  The Spectrum of Bladder Health: The Relationship Between Lower Urinary Tract Symptoms and Interference with Activities.

Authors:  Siobhan Sutcliffe; Tamara Bavendam; Charles Cain; C Neill Epperson; Colleen M Fitzgerald; Sheila Gahagan; Alayne D Markland; David A Shoham; Ariana L Smith; Mary K Townsend; Kyle Rudser
Journal:  J Womens Health (Larchmt)       Date:  2019-05-06       Impact factor: 2.681

5.  Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder.

Authors:  Tamako A Garcia; Christy L Ventura; Mark A Smith; D Scott Merrell; Alison D O'Brien
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

6.  Host-specific induction of Escherichia coli fitness genes during human urinary tract infection.

Authors:  Sargurunathan Subashchandrabose; Tracy H Hazen; Ariel R Brumbaugh; Stephanie D Himpsl; Sara N Smith; Robert D Ernst; David A Rasko; Harry L T Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

7.  In vivo gene expression analysis identifies genes required for enhanced colonization of the mouse urinary tract by uropathogenic Escherichia coli strain CFT073 dsdA.

Authors:  Brian J Haugen; Shahaireen Pellett; Peter Redford; Holly L Hamilton; Paula L Roesch; Rodney A Welch
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

8.  Excessive antibiotic use in men with prostatitis.

Authors:  Brent C Taylor; Siamak Noorbaloochi; Mary McNaughton-Collins; Christopher S Saigal; Min-Woong Sohn; Michel A Pontari; Mark S Litwin; Timothy J Wilt
Journal:  Am J Med       Date:  2008-05       Impact factor: 4.965

9.  The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection.

Authors:  Kelsey E Sivick; Matthew A Schaller; Sara N Smith; Harry L T Mobley
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

10.  α-Intercalated cells defend the urinary system from bacterial infection.

Authors:  Neal Paragas; Ritwij Kulkarni; Max Werth; Kai M Schmidt-Ott; Catherine Forster; Rong Deng; Qingyin Zhang; Eugenia Singer; Alexander D Klose; Tian Huai Shen; Kevin P Francis; Sunetra Ray; Soundarapandian Vijayakumar; Samuel Seward; Mary E Bovino; Katherine Xu; Yared Takabe; Fábio E Amaral; Sumit Mohan; Rebecca Wax; Kaitlyn Corbin; Simone Sanna-Cherchi; Kiyoshi Mori; Lynne Johnson; Thomas Nickolas; Vivette D'Agati; Chyuan-Sheng Lin; Andong Qiu; Qais Al-Awqati; Adam J Ratner; Jonathan Barasch
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.